索引于
- 打开 J 门
- Genamics 期刊搜索
- 学术钥匙
- 期刊目录
- 参考搜索
- 哈姆达大学
- 亚利桑那州EBSCO
- SWB 在线目录
- 普布隆斯
- 日内瓦医学教育与研究基金会
- 欧洲酒吧
- 谷歌学术
分享此页面
期刊传单
抽象的
Medicine Withdrawal and Recall: Needs Proper Evaluation
Chetna Patel and Shashank Deoghare
Currently, withdrawal and recall of medicines become a hot topic of discussion. This issue does not follow a uniform pattern all over the world. Few medicines continue to remain in the market despite reported adverse effects. This is understandable because:
• They may be the only available options for a few sets of patients e.g. felbamate (anti-epileptic)
• Drug remains in the market until better options are available in terms of safety and efficacy e.g. terfenadine approved in 1985 was found to cause cardiac arrhythmias but it continued to be in the market till the arrival of newer analogue fexofenadine in 1997.
• Withdrawal may also become the last option to choose if all other risk management techniques fail as was observed in the case of heartburn treatment with cisapride